Degradation of CTLA-4 balances toxicity and efficacy

Ren, Zhenhua; Fu, Yang

doi:10.1016/j.scib.2019.07.028

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the ADCC strategy is unlikely to succeed in colorectal, liver, prostate and ovarian cancer treatments [ 170 , 171 ]. Ipilimumab is the first immune checkpoint blockade (ICB) that was approved by FDA for treating metastatic melanomas [ 172 ]. Despite the prolonged survival of patients, anti-CTLA-4 antibody treatment can cause severe immunotherapy-related adverse effects (irAEs), which significantly limits its clinical benefits.…”

Section: Tumour Immunotherapy Strategies Targeting Tregsmentioning

confidence: 99%

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

et al. 2020

View full text Add to dashboard Cite

Regulatory T cells (Tregs) characterized by the expression of the master transcription factor forkhead box protein p3 (Foxp3) suppress anticancer immunity, thereby hindering protective immunosurveillance of tumours and hampering effective antitumour immune responses in tumour-bearing hosts, constitute a current research hotspot in the field. However, Tregs are also essential for the maintenance of the immune tolerance of the body and share many molecular signalling pathways with conventional T cells, including cytotoxic T cells, the primary mediators of tumour immunity. Hence, the inability to specifically target and neutralize Tregs in the tumour microenvironment without globally compromising self-tolerance poses a significant challenge. Here, we review recent advances in characterizing tumour-infiltrating Tregs with a focus on the functional roles of costimulatory and inhibitory receptors in Tregs, evaluate their potential as clinical targets, and systematically summarize their roles in potential treatment strategies. Also, we propose modalities to integrate our increasing knowledge on Tregs phenotype and function for the rational design of checkpoint inhibitor-based combination therapies. Finally, we propose possible treatment strategies that can be used to develop Treg-targeted therapies.

show abstract

Section: Tumour Immunotherapy Strategies Targeting Tregsmentioning

confidence: 99%